Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.35 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2370810 | 0.84 | ACHE (0.36) | TBK1IKBKEACHEBACE1IDO1 | |
| SCHEMBL2371455 | 0.77 | TET2 (0.34) | TBK1TET2IDO1KDM4EALDH1A1 | |
| SCHEMBL2370967 | 0.72 | TBK1 (0.44) | TBK1IDO1KDM4EALDH1A1MEN1 | |
| SCHEMBL2371223 | 0.72 | TDO2 (0.38) | ACHEBACE1 | |
| SCHEMBL29693906 | 0.72 | TBK1 (0.44) | TBK1IDO1KDM4EALDH1A1MEN1 | |
| SCHEMBL12468860 | 0.71 | NPC1 (0.41) | ACHEBACE1BCHEKDM4EALDH1A1 | |
| SCHEMBL19181427 | 0.63 | TBK1 (0.77) | TBK1IKBKEKDM4E | |
| SCHEMBL2515750 | 0.63 | NPC1 (0.39) | ACHEBACE1BCHEKDM4EALDH1A1 | |
| SCHEMBL2371020 | 0.63 | ALDH1A1 (0.69) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2370815 | 0.63 | NPC1 (0.45) | ACHEBACE1KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | TBK1 2235/4885IKBKE 894/4885TET2 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.